Raphaël Wisniewski

Partner, Life Sciences at Andera Partners SCA

Raphaël Wisniewski

Raphaël Wisniewski

Partner, Life Sciences at Andera Partners SCA

Overview
RelSci Relationships

4693

Number of Boards

37

Birthday

1970

Age

51

Contact Data
Trying to get in touch with Raphaël Wisniewski? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Raphaël Wisniewski likely has professional access to. A relationship does not necessarily indicate a personal connection.

Partner at Kurma Partners SA

Relationship likelihood: Strong

Former Chief Executive Officer, Founder at Axonics Modulation Technologies, Inc.

Relationship likelihood: Strong

President, Chief Executive Officer & Director at Chase Therapeutics Corp.

Relationship likelihood: Strong

Partner, Life Sciences at Andera Partners SCA

Relationship likelihood: Strong

Founder at ReViral Ltd.

Relationship likelihood: Strong

Co-Founder at ReViral Ltd.

Relationship likelihood: Strong

Venture Partner, Life Sciences at Andera Partners SCA

Relationship likelihood: Strong

Partner, Life Sciences at Andera Partners SCA

Relationship likelihood: Strong

General Partner at Kreos Capital Management (UK) Ltd.

Relationship likelihood: Strong

Partner, Growth Capital Mid Caps at Andera Partners SCA

Relationship likelihood: Strong

Paths to Raphaël Wisniewski
Potential Connections via
Relationship Science
You
Raphaël Wisniewski
Partner, Life Sciences at Andera Partners SCA
Education
Undergraduate Degree

Founded in 1881 by the Paris Chamber of Commerce and Industry, HEC Paris specializes in education and research in management sciences. As a leading academic institution in Europe and worldwide, HEC Paris offers a complete and unique range of education programs for students and leaders. HEC Paris has a permanent faculty of 106 professors, 4,000 students and over 8,500 managers in executive education programs every year.

Sciences Po aims to offer education firmly rooted in five social science disciplines: economics, law, history, sociology and political science. It stands out for a multidisciplinary approach and a focus on students' ability to understand and analyse complexity. This is an indispensable quality to move forward in constantly changing environments. The education and degrees offered at Sciences Po meet international standards and are recognised by the most renowned universities. Some of these universities have developed dual-degree programmes with Sciences Po at the Bachelor, Master and PhD levels. Our degrees are also prized by recruiters, and the ease with which our students incorporate the international labour market illustrates the value of our education.

Paris-Sorbonne University (also known as Paris IV; French: Université Paris-Sorbonne, Paris IV), was a public research university in Paris, France, from 1971 to 2017. Paris IV was one of the inheritors of the Faculty of Humanities of the University of Paris[1] (also known as the Sorbonne), which ceased to exist following student protests in May 1968. As such, it is a successor of the Sorbonne, whose original focus was humanities.[2] It is a member of the Sorbonne University Group and will merge into the Sorbonne University.[3][4] The university enrolls about 24,000 students in 20 departments specializing in arts, humanities and languages, divided in 12 campuses in Paris. Seven of the campuses are situated in the historic Latin Quarter, including the historic Sorbonne university building, and three in the Marais, Malesherbes and Clignancourt respectively. Paris-Sorbonne also houses France's prestigious communication and journalism school, CELSA, located in the Parisian suburb of Neuilly-sur-Seine, maintains about 400 international agreements.

Career History
Partner, Life Sciences
2002 - Current

Andera Partners is an activist investment manager with a long-term outlook. The firm invests in European companies with high-growth potential, focusing on France and occasionally investing in Germany, Belgium, the Netherlands and Switzerland. They acquire significant minority interests in unlisted companies whose managers are major shareholders, and seek board representation. Andera Partners targets companies in need of capital to fuel organic growth, to engage in acquisitions or to face liquidity events. They also target innovation-based companies with distinctive technology and businesses in life science sectors such as therapeutic products, medical equipment and molecular diagnostics. Additionally, Andera Partners seeks to invest in pre-IPO, PIPE and public-to-private situations.Andera Partners aims to facilitate the geographical, commercial, technological and industrial development of their portfolio companies. In addition to providing them with growth capital, Andera Partners promotes improvements in operational areas such as capital raising, shareholder structure, reporting, key personnel recruitment and business alliances.

Manager
Current
Partner
Prior

Goldman, Sachs & Co. (GS&Co.), a limited partnership registered as a U.S. broker-dealer and futures commission merchant, together with its consolidated subsidiaries (collectively, the firm), is an indirectly wholly owned subsidiary of The Goldman Sachs Group, Inc. (Group Inc.), a Delaware corporation. The firm is a leading global investment banking, securities and investment management firm that provides a wide range of financial services to a substantial and diversified client base that includes corporations, financial institutions, governments and high-net-worth individuals.

Boards & Committees
Chairman-Supervisory Board
Current
Director
Current

ReViral Ltd. specializes in the areas of virology and antiviral therapies. It offers drugs to treat respiratory synctial virus infection. The company was founded by Neil Matthews and Stuart Cockerill in 2011 and is headquartered in Stevenage, the United Kingdom.

Director
Current
Transactions
Details Hidden

Allergan Ltd. (Ireland) purchases Chase Pharmaceuticals Corp. from Andera Partners SCA, Brain Trust Accelerator Fund, Cipla Ventures

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Raphaël Wisniewski. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Raphaël Wisniewski's profile does not indicate a business or promotional relationship of any kind between RelSci and Raphaël Wisniewski.